Valeant Pharmaceuticals (NYSE:VRX) commences a private offering of $9.6B aggregate principal amount of senior unsecured notes. The debt, together with the company's incremental term loan facilities and cash on hand, will fund the acquisition of Salix Pharmaceuticals (NASDAQ:SLXP).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.